GENE ONLINE|News &
Opinion
Blog

2022-07-28| Technology

HIV Latent Cells Could Lead to Possible Cure

by Max Heirich
Share To

On July 27, scientists with the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC) announced at AIDS 2022, the 24th International AIDS Conference in Montreal, that they have found new insights which could lead to a potential cure for HIV. 

Related Article: Ascletis Begins Study of PD-L1 Antibody Candidate Against HIV

Cutting-Edge Technology Reveals New Insights

Technology limitations have made it difficult for researchers to gain an enhanced understanding of HIV-infected, memory CD4+ T cells. These are T cells that help coordinate the body’s immune response. However, HIV interrupts that function, which destroys the cells. The infected cells can linger for decades in an individual. Due to the limitations of technology, scientists have been unable to get a clear picture of what, if any, distinct attributes they might have. If found, an HIV-cure-directed therapy could exploit these attributes.

However, at the conference, Eli Boritz, M.D., Ph.D., chief of the Virus Persistence and Dynamics Section in the VRC Laboratory of Immunology, conducted a presentation wherein he revealed new technology that could show apparent differences between HIV-infected CD4+ T cells and uninfected cells. As a result of a collaboration between NIAID and a bioengineering group at the University of California, Sacramento, researchers have developed a new microfluidic sorting technology.

This new advancement allows scientists to define gene expression patterns by dubbed Focused Interrogation of Cells by Nucleic Acid Detection and Sequencing (FIND-Seq). This works by segregating cells into millions of different single-cell containers. Then, scientists perform messenger RNA capture and virus DNA detection sequentially.

After applying FIND-Seq to the blood cells of six HIV-infected individuals, scientists compared the gene expressions of infected CD4+ T cells to uninfected cells of the same type in the same individual. The scientists found a distinct difference in the gene expressions between the infected and uninfected cells. The infected population might be susceptible to therapies targeting their gene expression.

As outlined in a release summarizing the presentation, the results of FIND-Seq have renewed scientific interest in developing targeted therapies that could induce the death of HIV-infected cells. With this new method of examining the gene expression of these cells, researchers can now think ahead to what might be the next step in HIV cure research. 

Related Article: Innovating Drug Delivery Systems with Moderna’s Bob Langer

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Gilead Touts Long-Term Efficacy And Safety Data For HIV Drug
2022-10-26
Merck’s Phase 2 HIV Treatment Study Resumes with Phase 3 Program Announcement
2022-09-20
A Cure for HIV Could Be Here Sooner Than You Think – Future of Health
2022-09-16
LATEST
Junshi’s PD-1 Antibody Meets Endpoint In Phase 3 Lung Cancer Trial
2023-01-19
Moderna Welcomes Phase 3 Win For RSV Vaccine
2023-01-18
Moving Beyond COVID With mRNA Technology
2023-01-18
Rob Knight and Jing-Yuan Fu Elaborate On Microbiome Research Trends at the 7th Asia Microbiome Conference(AMC)
2023-01-17
CARsgen Taps Huadong to Commercialize Multiple Myeloma CAR-T in China
2023-01-17
Scientists Study Imaging Probes in First-Ever Amputated Human Limb Model
2023-01-16
EMA Plans to Issue Liver Failure Warning for Novartis’ Gene Therapy
2023-01-16
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!